Notch pathway plays an important role in lung cancer biology.

Data show that shRNA against NOTCH3 resulted in a significant decrease in ALDH(+) lung cancer cells, commensurate with a reduction in tumor cell proliferation and clonogenicity.

Studied Notch3 expression in NSCLC tissues and adjacent non-cancerous normal lung tissues over a period of 5 yrs. Notch3 had high expression in 67 of 131 cases of NSCLC, which was significantly higher than in adjacent noncancerous lung tissues.

Notch3 plays a nonredundant role in tumor cell propagation in two mouse models and in human non-small-cell lung cancer.

Notch3 plays a role in the cell proliferation and apoptosis induced by CHIR99021 in non-small-cell lung cancer cell lines.

Wnt3a and Notch3 may promote the metastasis of non-small cell lung cancer and Notch3 upregulation is required for the Wnt3a mediated increased metastatic abilities of non-small cell lung cancer.

Loss of Notch3 expression is associated with small cell lung carcinoma.

NOTCH3 single-nucleotide polymorphisms role in susceptibility to non-small cell lung cancer

hus Notch3 appears to be a promising target for gene therapy and DAPT is able to mediate a strong antitumor effect in nonsmall cell lung cancer (NSCLC) cells that overexpress Notch3. Further studies of a combined treatment regimen with DAPT and GEM are warranted and may provide greater efficacy and safety in the treatment of NSCLC patients

Notch3 rs3815188, DLL1 rs1033583, JAG1 rs8708, JAG2 rs9972231, HEY1 rs1046472, HEY2 rs3734637 and HES2 rs11364 were significantly associated with susceptibility to lung cancer.

The rs3815188 variant and rs1043994 variant of the Notch3 gene is associated with lung cancer risk in patients of Turkish origin.

Ectopic expression of Notch3 in airway epithelium potentially contributes to the multistep evolution of lung cancer through the inhibition of terminal differentiation.